

NEWSLETTER

September 2025

Dear Friends and Investors,

I'm excited to share a brief update on RegenMed's progress. We've had a busy season, advancing partnerships, strengthening our investor position, and extending our reach in both healthcare innovation and academic collaboration. Here are four highlights we're proud of:

Partnering with OREF to Launch MOTIV™

Together with the Orthopaedic Research and Education Foundation, we launched **MOTIV™**, a peer-reviewed library of real-world evidence datasets in musculoskeletal medicine. This is a milestone toward replacing unverifiable “big data” with **clinically rigorous, FDA-fit datasets** that improve patient outcomes and support value-based care.

RegenMed

TRANSFORMING
MUSCULOSKELETAL
RESEARCH WITH
REAL-WORLD EVIDENCE



READ MORE

Sponsoring UW–Madison’s Capstone Project

RegenMed

REGENMED SPONSORS UNIVERSITY
OF WISCONSIN CAPSTONE PROJECT
TO ADVANCE PATIENT-REPORTED
OUTCOMES IN HEALTHCARE



We're investing in the next generation of innovators by sponsoring a **University of Wisconsin Computer Sciences Capstone team**. Students will enhance our patient-reported outcomes (ePRO) platform with gamification and UX improvements, mentored by RegenMed leaders. We join sponsors like **Epic, Google, and GE HealthCare** in supporting this nationally recognized program.


READ MORE

NEWSLETTER

September 2025

Welcoming HyperFlex Medical as a New Client

We're proud to add **HyperFlex Medical** to our growing client base. Their **HyperFlex® Bunion Correction System** is a minimally invasive, bone-preserving solution for the **23% of adults affected by bunions**. With a market projected to grow from **\$1.47B in 2023 to \$2.33B by 2032**, this partnership shows how RegenMed Circles support both innovation and scale in high-demand specialties.



[READ MORE](#)

Launching Our New Investor Page



We've launched a dedicated Investor Page, outlining why RegenMed is a **Zero-to-One company** in a **\$100B+ healthcare data market**. With strong recurring revenues, AI-ready infrastructure, and early investor momentum, we believe we're building one of the most compelling opportunities in healthcare data today.

[VISIT THE INVESTOR PAGE](#)

We're grateful for your continued support as we scale RegenMed's mission to make real-world healthcare data both **trustworthy and transformative**. Stay tuned for more updates, and reach out any time.



Warm regards,
Michael P. Tierney
 CEO, RegenMed